Drugs for rare and end-of-life conditions get Scottish cash boost
This article was originally published in Scrip
Executive Summary
The Scottish government has allotted £80m to the New Medicines Fund, which is used to help pay for treatments for patients with rare or end-of-life conditions, for 2015-16. This is double the amount given to the fund in the previous year, and will help pay for the expected rise in the number of such products being recommended by the HTA body, the Scottish Medicines Consortium (SMC).